Published in Blood Weekly, September 23rd, 2004
According to a study from Italy, "Acute myeloid leukemia is a heterogeneous disease that presents with a range of morphological, cytogenetic, immunophenotypic, and biomolecular features. Over the past 20 years, application of new cytogenetic and molecular techniques has greatly improved knowledge of the pathophysiology of AML, resulting in new potential therapeutic applications."
"However," noted F. Ferrara, Cardarelli General Hospital, Naples, "the results of current therapy are still unsatisfactory, especially in patients who have adverse prognostic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.